KUALA LUMPUR, Sept 8 (Bernama) -- Bursa Malaysia closed almost flat on Tuesday as buying interest rotated away from index heavyweights towards smaller-cap construction stocks, with sentiment affected by geopolitical uncertainty, said an analyst. At 5 pm, the FTSE Bursa Malaysia KLCI (FBM KLCI) eased 0.39 of a point to 1,714.40 from Monday’s close of 1,714.79. The benchmark index opened 1.65 points lower at 1,713.14 and moved between 1,710.44 and 1,714.50 throughout the trading session. The broader market was almost evenly balanced, with decliners leading gainers 548 to 546, while 598 counters were unchanged, 1,107 were untraded and 25 were suspended. Turnover expanded to 4.13 billion units valued at RM3.14 billion from 3.60 billion units valued at RM2.45 billion on Monday.
Not all rallies scream with hype. Some, like Harbin Pharmaceutical Group, climb quietly — backed not by noise, but by solid fundamentals.
- +11% in the past month.
- 57% earnings growth over five years.
- ROE of 11% vs. industry average of 7.1%.
These aren’t meme metrics — these are the hallmarks of a business executing well behind the scenes.
What’s Driving It?
Efficient capital use: For every ¥1 in equity, Harbin Pharma returns ¥0.11 in profit.
Reinvesting 100% of its earnings. No dividends. Just pure business reinvestment.
Outpaced its industry: While peers averaged 6.2% net income growth, Harbin clocked in 57%.
That’s the kind of compounding investors dream of — and rarely find without digging.
But Here’s the Twist…
Analysts expect earnings growth to slow down. Whether that’s a sector-wide sentiment shift or a real red flag depends on how well management can continue allocating capital effectively.
Stock Picker’s Take:
This is a “sleep well at night” stock for patient investors — one that may be flying under the radar while quietly building long-term value.
Comments
Post a Comment